Publication | Closed Access
A Phase 1 Study of Combotox in Pediatric Patients With Refractory B-lineage Acute Lymphoblastic Leukemia
90
Citations
18
References
2009
Year
Combotox can be safely administered to children with refractory leukemia. It has clinically important anticancer activity as a single agent. The recommended dose for future studies is 5 mg/m2/dose.
| Year | Citations | |
|---|---|---|
Page 1
Page 1